Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 6/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133747 | 0.88 | PDE5A (0.51) | PNPGDAPDE5AXDHGRIA1 | |
| SCHEMBL9220662 | 0.86 | PNP (0.42) | PNPGDAPDE5AXDHGRIA1 | |
| SCHEMBL9275484 | 0.85 | PNP (0.48) | PNPGDAPDE5AXDHGRIA1 | |
| SCHEMBL4999431 | 0.81 | PNP (0.43) | PNPGDAPDE5AXDHGRIA1 | |
| SCHEMBL595204 | 0.77 | PNP (0.57) | PNPGDAXDHGRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL17186227 | 0.76 | PNP (0.56) | PNPGDAXDHGRIA1GRIA2 | |
| SCHEMBL8591405 | 0.74 | GDA (0.52) | PNPGDAXDHGRIA1GRIA2 | |
| SCHEMBL2435286 | 0.72 | GDA (0.57) | PNPGDAXDHGRIA1GRIA2 | |
| SCHEMBL473739 | 0.72 | PDE5A (0.47) | PNPGDAPDE5AXDHGRIA1 | |
| SCHEMBL27668926 | 0.72 | PNP (0.42) | PNPGDAPDE5AXDHGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | claimed |
| EP-4499710-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | Precision Biologics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240400714-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240384003-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PREC BIOLOGICS INC (US) | 2024-11-21 | — | — | US | claimed |
| EP-4352103-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Precision Biologics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2023225608-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PRECISION BIOLOGICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2022246066-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PRECISION BIOLOGICS, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20210002383-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2021-01-07 | — | — | US | claimed |
| EP-3752533-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | Precision Biologics, Inc. (US) | 2020-12-23 | — | — | EP | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-20170304310-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | claimed |
| WO-2016145186-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-9439884-B2 | Methods for the treatment of immune disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-13 | — | — | US | claimed |
| EP-2858648-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | Beth Israel Deaconess Medical Center, Inc. (US) | 2015-04-15 | — | — | EP | claimed |
| US-20140219957-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-07 | — | — | US | claimed |
| WO-2013185055-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-12-12 | — | — | WO | claimed |
| WO-2012162698-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| US-20100144618-A1 | Compositions containing an intestinal trefoil peptide and a mucoadhesive | PODOLSKY DANIEL K | 2010-06-10 | — | — | US | claimed |
| US-20060189526-A1 | COMPOSITIONS CONTAINING AN INTESTINAL TREFOIL PEPTIDE AND A MUCOADHESIVE | THE GENERAL HOSPITAL CORPORATION | 2006-08-24 | — | — | US | claimed |
| US-5879323-A | IONOPHORETIC TRANSDERMAL DELIVERY OF A 2-HYDROXYETHOXY(METHYL)GUANINE INTO TISSUES OVERLYING MUCOCUTANEOUS HERPES TYPE I AND TYPE II INFECTIONS | THE APS ORGANIZATION, LLP (US) | 1999-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | CD47, SIGLEC9, LGALS1 | PNP 1734/4885GDA 377/4885PDE5A 2371/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | PNP 3259/4885GDA 834/4885PDE5A 4568/4885 |
| US-20170304310-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | PIN1, FKBP1A, FKBP2 | PNP 2595/4885GDA 2728/4885PDE5A 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.